Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kinan Alhallak

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Immunity|May 31, 2024
Mast cells control lung type 2 inflammation via prostaglandin E<sub>2</sub>-driven soluble ST2Kinan Alhallak, Jun Nagai, Kendall Zaleski, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 3, 2017
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myelomaPilar de la Puente, Micah J Luderer, Cinzia Federico, et al.
Leukemia|August 30, 2024
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myelomaJennifer Sun, Stefan Corradini, Feda Azab, et al.
Nature Communications|November 28, 2020
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myelomaCinzia Federico, Kinan Alhallak, Jennifer Sun, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Immunity|May 31, 2024
Mast cells control lung type 2 inflammation via prostaglandin E<sub>2</sub>-driven soluble ST2Kinan Alhallak, Jun Nagai, Kendall Zaleski, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 3, 2017
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myelomaPilar de la Puente, Micah J Luderer, Cinzia Federico, et al.
Leukemia|August 30, 2024
IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myelomaJennifer Sun, Stefan Corradini, Feda Azab, et al.
Nature Communications|November 28, 2020
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myelomaCinzia Federico, Kinan Alhallak, Jennifer Sun, et al.
Pageof 3